The use of Aerocrine’s FeNO-measuring device NIOX VERO as a tool for assessing patients with allergic airway inflammation has been cleared by Japanese health authorities.
The Japanese Pharmaceuticals and Medical Devices Agency’s (PMDA) has granted Aerocrine regulatory clearance for NIOX VERO. NIOX VERO is the company’s next generation device for measuring Fractional Nitric Oxide (FeNO) levels in clinical settings. The clearance in Japan follows the FDA approval in the US in November 2014.
Aerocrine’s NIOX MINO and now NIOX VERO are the only FeNO measuring devices cleared by both the PMDA in Japan and also FDA in the United States.